Nasopharyngeal flora and drug susceptibility in children with macrolide therapy

Laryngoscope

Volumn 113, Issue 10, 2003, Pages 1780-1785

  Iino, Yukiko ^a   Sasaki, Yukako ^b   Miyazawa, Tesuo ^b   Kodera, Kazuoki ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Chronic rhinosinusitis; Drug resistant bacteria; Erythromycin resistant Streptococcus pneumoniae; Macrolide therapy; Otitis media with effusion

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN G;

AGE DISTRIBUTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL FLORA; BACTERIUM CARRIER; BACTERIUM CULTURE; BACTERIUM ISOLATION; CHILD; CONTROLLED STUDY; DRUG DOSE REGIMEN; ERYTHROMYCIN RESISTANT STREPTOCOCCUS PNEUMONIAE; FEMALE; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; NASOPHARYNGEAL FLORA; NOSE SMEAR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHINOSINUSITIS; RISK FACTOR; SECRETORY OTITIS MEDIA; SEX DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; THROAT CULTURE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MACROLIDES; MALE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; NASOPHARYNX; OTITIS MEDIA WITH EFFUSION; PNEUMOCOCCAL INFECTIONS; PROSPECTIVE STUDIES; RHINITIS; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

EID: 0141529791     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200310000-00023     Document Type: Article

References (30)

1. Kudo S, Uetake T, Hagiwara K, et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [in Japanese]. Jpn J Thorac Dis 1987;25:632-642.
2. Kikuchi S, Suzaki H, Aoki A, Ito O, Nomura Y. Clinical effects of low-dose long-term erythromycin therapy for chronic sinusitis [in Japanese]. Pract Otol (Kyoto) 1991;84:41-47.
3. Iino Y, Sugita K, Toriyama M, Kudo K. Erythromycin therapy for otitis media with effusion in sinobronchial syndrome. Arch Otolaryngol Head Neck Surg 1993;119:648-651.
4. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998;351:420.
5. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement M100-S11. Wayne, PA: National Committee for Laboratory Standards, 2001.
6. Iino Y, Toriyama M, Kudo K, Natori Y, Yuo A. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol 1992;101(Suppl 157):16-20.
7. Takeshita K, Yamagishi I, Harada M, Otomo S, Nakagawa T, Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res 1989;15:527-33.
8. Anderson R, Fernandes AC, Eftychis HE. Studies on the effects of ingestion of a single 500 mg oral dose of erythromycin stearate on leukocyte motility and transformation and on release in vitro of prostaglandin E2 by stimulated leukocytes. J Antimicrob Chemother 1984;14:41-50.
9. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis 1989;159:966-973.
10. Sato E, Nelson DK, Koyama S, Hoyt JC, Robbins RA. Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro. Antimicrob Agents Chemother 2001;45:401-406.
11. Akamatsu H, Yamawaki M, Horio T. Effects of roxithromycin on adhesion molecules expressed on endothelial cells of the dermal microvasculature. J Int Med Res 2001;29:523-527.
12. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-163.
13. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 2002;360:978-984.
14. Ito M, Yoshizaki T, Hishimura T, Miwa T, Furukawa M. Nasopharyngeal penicillin-resistant Streptococcus pneumoniae strains among young children in Japan. Otol Neurotol 2002;23:349-352.
15. Dudley S, Ashe K, Winther B, Hendley JO. Bacterial pathogens of otitis media and sinusitis: detection in the nasopharynx with selective agar media. J Lab Clin Med 2001;138:338-342.
16. Hemlin C, Brauner A, Carenfelt C, Wretlind B. Nasopharyngeal flora in otitis media with effusion: a comparative semi-quantitative analysis. Acta Otolaryngol 1991;111:556-561.
17. Clary RA, Bahadori RS, Munts HR, Lusk RP. Bacteria in the middle ear and nasopharynx during tympanostomy tube insertion. Am J Otolaryngol 1998;19:301-304.
18. Marchisio P, Esposito S, Schito GC, Marchese A, Cavagna R, Principi N. Hercules Project Collaborative Group. Emerg Infect Dis 2002;8:479-484.
19. Tamaoki J, Chiyotami A, Sakai N, Takeyama K, Takizawa T. Effect of erythromycin on ciliary motility in rabbit airway epithelium in vitro. J Antimicrob Chemother 1992;29:173-178.
20. Tamaoki J, Kakeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol 1997;272:L15-L19.
21. Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990;141:72-78.
22. Takahashi Y, Shimizu T, Sakakura Y. Effects of indomethacin, dexamethason, and erythromycin on endotoxin-induced intraepithelial mucus production of rat nasal epithelium. Ann Otol Rhinol Laryngol 1997;106:683-687.
23. Gullemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998;279:365-370.
24. Bean DC, Klena JD. Prevalence of erm (A) and mef (B) erythromycin resistance determinants in isolates of Streptococcus pneumoniae from New Zealand. J Antimicrob Chemother 2002;50:597-599.
25. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated form the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002;50(Suppl S1):39-47.
26. Pihalajarnaki M, Kotilainen P, Kaurila T, Klaukka t, Palva E, Huovinen P, Finnish Study Group for Antimicrobial Resistance. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001;33:483-488.
27. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis: Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg 2000;125:5-31.
28. Dowell S, Bulter JC, Giebind GS, the Drug Resistant Streptococcus pneumoniae Therapeutic Working Group. Acute otitis media: management and surveillance in an era of pneumococcal resistance. Pediatr Infect Dis J 1999;18:1-9.
29. De Lencastre H, Kristinsson KG, Brito-Avo A, et al. Carriage of respiratory tract pathogens and molecular epidemiology of Streptococcus pneumoniae colonization in healthy children attending day care centers in Lisbon, Portugal. Microb Drug Resist 1999;5:19-29.
30. Cuffini AM, Tullio V, Mandras N, et al. Clarithromycin mediated the expression of polymorphonuclear granulocyte response against Streptococcus pneumoniae strains with different patterns of susceptibility and resistance of penicillin and clarithromycin. Int J Tissue React 2002;24:37-44.